Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement

Journal of Biomedical Nanotechnology

Volumn 9, Issue 11, 2013, Pages 1862-1874

  Jain, Sanyog ^a   Sharma, Jagadish M ^a   Agrawal, Ashish K ^a   Mahajan, Rahul R ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Antisolvent precipitation; Efavirenz; High pressure homogenization; Nanocrystals; Nanoparticles

Indexed keywords

ANTI-SOLVENT PRECIPITATIONS; CORRELATION COEFFICIENT; EFAVIRENZ; HIGH PRESSURE HOMOGENIZATION; HYDROXY PROPYL METHYL CELLULOSE; ORAL BIOAVAILABILITIES; PARTICLES SIZE DISTRIBUTION; STABILIZED NANOPARTICLES;

BIOCHEMISTRY; HOMOGENIZATION METHOD; NANOCRYSTALS; NANOPARTICLES; PARTICLE SIZE; PARTICLE SIZE ANALYSIS;

PRECIPITATION (CHEMICAL);

EFAVIRENZ; NANOCARRIER;

AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FREEZE DRYING; IN VITRO STUDY; INFRARED SPECTROSCOPY; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; PRECIPITATION; SURFACE PROPERTY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BENZOXAZINES; BIOLOGICAL AVAILABILITY; DIFFUSION; DRUG STABILITY; EXCIPIENTS; MALE; MATERIALS TESTING; METABOLIC CLEARANCE RATE; NANOCAPSULES; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES;

EID: 84883687649     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1683     Document Type: Article

References (34)

1. D. A. Chiappetta, C. Hocht, C. Taira, and A. Sosnik, Efavirenzloaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanomedicine 5, 11 (2010).
2. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413 (1995).
3. S. E. Starr, C. V. Fletcher, S. A. Spector, R. C. Brundage, F. H. Yong, S. D. Douglas, P. M. Flynn, and M. W. Kline, Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 21, 659 (2002).
4. T. Dutta, H. B. Agashe, M. Garg, P. Balasubramanium, M. Kabra, and N. K. Jain, Poly(propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target 15, 89 (2007).
5. T. Dutta, M. Garg, and N. K. Jain, Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm Sci. 34, 181 (2008).
6. S. Sathigari, G. Chadha, Y. H. P. Lee, N. Wright, D. L. Parsons, V. K. Rangari, O. Fasina, and R. J. Babu, Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS Pharm. Sci. Tech. 10, 81 (2009).
7. D. A. Chiappetta, C. Hocht, C. Taira, and A. Sosnik, Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials 32, 2379 (2011).
8. B. B. Madhavi, B. Kusum, C. H. Krishna Chatanya, M. N. Madhu, V. Sri Harsha, and D. Banji, Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniques. Int. J. Pharma. Investig. 1, 29 (2011).
9. L. Gao, D. Zhang, and M. Chen, Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 10, 845 (2008).
10. B. E. Rabinow, Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785 (2004).
11. K. Riehemann, S. W. Schneider, T. A. Luger, B. Godin, M. Ferrari, and H. Fuchs, Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. 48, 872 (2009).
12. Y. Wu, A. Loper, E. Landis, L. Hettrick, L. Novak, K. Lynn, C. Chen, K. Thompson, R. Higgins, and U. Batra, The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135 (2004).
13. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao, Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today 16, 354 (2011).
14. L. S. Bernardi, P. R. Oliveira, F. S. Murakami, M. A. S. Silva, S. H. M. Borgmann, and S. G. Cardoso, Characterization of venlafaxine hydrochloride and compatibility studies with pharmaceutical excipients. J. Therm. Anal. Calorim. 97, 729 (2009).
15. B. Van Eerdenbrugh, J. Vermant, J. A. Martens, L. Froyen, J. Van Humbeeck, P. Augustijns, and G. Van den Mooter, A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. 98, 2091 (2008).
16. M. E. Matteucci, M. A. Hotze, K. P. Johnston, and R. O. Williams Iii, Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization. Langmuir 22, 8951 (2006).
17. H. Zhao, J. X. Wang, Q. A. Wang, J. F. Chen, and J. Yun, Controlled liquid antisolvent precipitation of hydrophobic pharmaceutical nanoparticles in a microchannel reactor. Ind. Eng. Chem. Res. 46, 8229 (2007).
18. S Jain, D. S. Chauhan, A. K. Jain, N. K. Swarnakar, H. Harde, R. R. Mahajan, D. Kumar, P. U. Valvi, M. Das, S. R. Datir, and K. Thanki, Stabilization of the nanodrug delivery systems by lyophilization using universal step-wise freeze drying cycle. Indian Patent 2559/DEL/2011 (2011).
19. L. Zhou, L. Yang, S. Tilton, and J. Wang, Development of a high throughput equilibrium solubility assay using miniaturized shakeflask method in early drug discovery. J. Pharm. Sci. 96, 3052 (2007).
20. E. R. Montgomery, A. L. Edmanson, S. C. Cook, and P. K. Hovsepian, Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation. J. Pharm. Biomed. Anal. 25, 267 (2001).
21. J. B. Dressman and H. Lennernäs, Oral Drug Absorption, Marcel Dekker, Newyork (2000).
22. G. Levy, Effect of dosage form on drug absorption a frequent variable in clinical pharmacology. Archives internationales de pharmacodynamie et de therapie 152, 59 (1964).
23. R. E. Bruns, Effects of experimental conditions on the estimation of kinetic parameters of the thermal decomposition of AZT using factorial design. J. Therm. Anal. Calorim. 79, 697 (2005).
24. A. K. Agrawal, P. N. Gupta, A. Khanna, R. K. Sharma, H. Chandrabanshi, N. Gupta, U. K. Patil, and S. Yadav, Development and characterization of in situ gel system for nasal insulin delivery. Pharmazie 65, 188 (2010).
25. A. K. Agrawal, M. Das, and S. Jain, In situ gel systems as' smart'carriers for sustained ocular drug delivery. Exp. Opin. Drug Deliv. 9, 383 (2012).
26. S. M. D'Addio and R. K. Prud'homme, Controlling drug nanoparticle formation by rapid precipitation. Adv. Drug Deliv. Rev. 63, 417 (2011).
27. A. I. Kim, M. J. Akers, and S. L. Nail, The physical state of mannitol after freeze-drying: Effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J. Pharm. Sci. 87, 931 (1998).
28. R. Cavalli, O. Caputo, M. E. Carlotti, M. Trotta, C. Scarnecchia, and M. R. Gasco, Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 148, 47 (1997).
29. S. De Chasteigner, G. Cave, H. Fessi, J. P. Devissaguet, and F. Puisieux, Freeze-drying of itraconazole-loaded nanosphere suspensions: A feasibility study. Drug Dev. Res. 38, 116 (1996).
30. S. Mahapatra, T. S. Thakur, S. Joseph, S. Varughese, and G. R. Desiraju, New solid state forms of the anti-HIV drug efavirenz. conformational flexibility and high Z' issues. Cryst. Growth Des. 10, 3191 (2010).
31. C. M. Keck and R. H. Muller, Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62, 3 (2006).
32. J. Zhang, H. Lv, K. Jiang, and Y. Gao, Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int. J. Pharm. 420, 180 (2011).
33. S. Jain, S. R. Patil, N. K. Swarnakar, and A. K. Agrawal, Oral delivery of doxorubicin using novel polyelectrolytes stabilized liposomes (Layersomes). Mol. Pharmaceutics 9, 2626 (2012).
34. S. Jain, J. M. Sharma, A. K. Jain, and R. R. Mahajan, Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nanomedicine (doi:10.2217/nnm.12.181) (2013).